FLT3 and acute myeloid leukemia: Currently, some clinical trials involving combination regimens with FLT3‐TKIs in AML have completed, including the combination of sorafenib and 5‐azacytidine, which is proven to be effective in untreated FLT3‐ITD–positive AML patients, with an overall response rate of 78% [26].